SNIPR Biome

Main focus: Treatment of bacterial infections

Company stage: Pre-clinical

Diseases: Bloodstream infections caused by E. coli, other infections

Genome editing tool: CRISPR-Cas

Funding stage: Private

Location: Copenhagen, Denmark

Website: https://www.sniprbiome.com/

Partners: Novo Nordisk

SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.

SNIPR Biome

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (3 February 2023) - Your Weekly CRISPR...

Feb. 3, 2023

Some of the best links we picked up around the internet

Clinical Trial Update: Encouraging Safety and...

Feb. 1, 2023

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...

CMN Weekly (27 January 2023) - Your Weekly CRISPR...

Jan. 27, 2023

Some of the best links we picked up around the internet

A Gene-Edited Cell Therapy for an Incurable...

Jan. 23, 2023

Professor Stephanie Cherqui of University of California San Diego’s School of Medicine recently received a prestigious grant from the Californian...

CMN Weekly (20 January 2023) - Your Weekly CRISPR...

Jan. 20, 2023

Some of the best links we picked up around the internet

Clinical Update: Gene-Editing Trials for Solid...

Jan. 18, 2023

In this clinical update, we look at four ongoing clinical trials involving a gene-edited therapeutic candidate for the treatment of solid cancers.